Company Description
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States.
The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
It is also developing RAD301 and RAD302, which are Avβ6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic.
The company was incorporated in 2021 and is based in Carlton, Australia.
| Country | Australia |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Riccardo Canevari |
Contact Details
Address: 62 Lygon Street, Level 3 Carlton, VIC 3053 Australia | |
| Phone | 61 3 9824 5254 |
| Website | radiopharmtheranostics.com |
Stock Details
| Ticker Symbol | RADX |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| CIK Code | 0001949257 |
| CUSIP Number | 75041J101 |
| ISIN Number | US75041J1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Riccardo Canevari | MD, Chief Executive Officer and Director |
| Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Founder and Executive Chairman |
| Dr. Dimitris Voliotis M.D. | Chief Medical Officer |
| Aaron Laurita | Chief Financial Officer |
| Hitesh Goel | Head of Project Management |
| Nathan Jong C.A. | Joint Company Secretary |
| Amritha Sushil | Joint Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | 6-K | Report of foreign issuer |
| Oct 26, 2026 | 6-K | Report of foreign issuer |
| Oct 20, 2026 | 6-K | Report of foreign issuer |
| Oct 14, 2026 | SCHEDULE 13G | Filing |
| Oct 5, 2026 | 6-K | Report of foreign issuer |
| Oct 1, 2026 | 6-K | Report of foreign issuer |
| Sep 30, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Sep 30, 2026 | 6-K | Report of foreign issuer |
| Sep 23, 2026 | EFFECT | Notice of Effectiveness |
| Sep 23, 2026 | 424B3 | Prospectus |